What is the recommended medication regimen for an acute psoriasis flare in an adult without contraindications?

Recommended Medication for Acute Psoriasis Flare

For an acute psoriasis flare in adults, initiate high-potency topical corticosteroids (class 1) combined with calcipotriene for localized disease, or cyclosporine for rapid control of severe/generalized flares, followed by transition to methotrexate, adalimumab, or ustekinumab for maintenance therapy. 1, 2, 3

Treatment Algorithm Based on Disease Extent

Localized Disease (Limited Body Surface Area)

• Start with ultrahigh-potency (class 1) topical corticosteroid plus calcipotriene as first-line therapy 1
• This combination provides rapid control while the calcipotriene component allows for corticosteroid-sparing maintenance
• Topical therapy remains the foundation for localized flares before escalating to systemic options

Generalized/Severe Disease or Erythrodermic Flares

Acute Phase (Rapid Control Needed):

• Cyclosporine is the preferred agent for acute management due to its rapid onset of action, achieving control in over 60% of cases 3
• This is particularly critical for erythrodermic presentations where systemic symptoms (fever, dehydration, electrolyte disturbances) require urgent intervention
• Cyclosporine should be used short-term only due to nephrotoxicity and hypertension risks 4

Transition to Maintenance Therapy: After achieving initial control with cyclosporine, transition to one of these evidence-based options:

1. Methotrexate (7.5-25 mg weekly, oral or subcutaneous) 5, 2

   • Recommended as primary systemic treatment by French guidelines 2
   • Strength of recommendation: A 5
   • Must co-administer folic acid to reduce GI and hepatic adverse effects 5
   • Monitor liver function every 3-6 months 5
   • Critical caveat: Screen for hepatotoxicity risk factors (alcohol use, fatty liver disease, hepatitis B/C) before initiating 5

2. Adalimumab (biologic TNF-inhibitor) 2

   • Recommended as primary systemic option alongside methotrexate and ustekinumab 2
   • More effective than methotrexate for cutaneous psoriasis 5
   • Can be combined with calcipotriene/betamethasone topicals for accelerated clearance (Strength B recommendation) 1

3. Ustekinumab (IL-12/23 inhibitor) 2

   • Recommended as primary systemic treatment option 2
   • Suitable for long-term maintenance

Enhanced Efficacy Strategies

Combination approaches to accelerate clearance:

• Adding ultrahigh-potency topical corticosteroid to etanercept (Strength A) 1
• Adding calcipotriene/betamethasone to adalimumab (Strength B) 1
• Adding topical calcipotriene to methotrexate (Strength A) 1

Critical Pitfalls to Avoid

1. Never abruptly stop systemic agents without tapering - this causes severe rebound flares 6
2. When transitioning between systemic therapies, overlap the new agent before discontinuing the old one to prevent rebound 6
3. Do not use methotrexate or acitretin in pregnancy - both are teratogenic 4
4. Avoid long-term continuous cyclosporine due to cumulative nephrotoxicity and malignancy risk 4
5. Screen for hepatotoxicity risk factors before methotrexate - baseline liver fibrosis assessment is mandatory 5

Newer High-Efficacy Options

For patients requiring maximum efficacy, the most recent evidence identifies these as the most effective agents 7:

• Infliximab, bimekizumab, ixekizumab, and risankizumab showed statistically similar superior effectiveness
• Risankizumab (IL-23 inhibitor) achieved PASI 90 in over 75% at week 16 3
• Secukinumab (IL-17 inhibitor) achieved PASI 75 in over 80% by week 8 3

These biologics are increasingly recommended as first-line options rather than being reserved for treatment failures, particularly for severe presentations 8.

Treatment Goals

• Minimum target: PASI 75 response
• Desirable goal: PASI 90 or absolute PASI <2 8